41st week of 2021 patent applcation highlights part 21 |
Patent application number | Title | Published |
20210317148 | Systems and Methods for Mechanosynthesis - Systems and methods for mechanosynthesis are disclosed, including those that avoid the need for a bootstrap process, avoid the need to build tips via mechanosynthesis, avoid the need for charging tips with feedstock during a build sequence, avoid the need to dispose of reaction byproducts, which reduce the design complexity of new tips, and/or which reduce or avoid the need for multiple positional means and/or tip switching. | 2021-10-14 |
20210317149 | BENZENE 1,4-BIS(BISPHOSPHONIC ACID)-BASED METAL COMPLEXES, METHOD OF SYNTHESIS AND APPLICATIONS THEREOF - The invention provides extended bisphosphonate-based metal complexes using benzene1,4-bis(bisphosphonic acid) (BBPA), an analog of benzene 1,4-dicarboxylic acid (BDC). Hydrothermal synthesis of BBPA with the bioactive metals Ca | 2021-10-14 |
20210317150 | CD73 INHIBITORS AND USES THEREOF - Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein. | 2021-10-14 |
20210317151 | RHENIUM COMPLEXES AND METHODS OF USE FOR TREATING CANCER - A composition comprising the following structure: (1) wherein Re represents a rhenium ion having a +1 charge; (I) represents an uncharged bidentate ligand containing at least one ring containing a ring nitrogen atom bound to the rhenium (Re), and the bidentate ligand containing another nitrogen atom, either in a ring or not in a ring, bound to the rhenium (Re); and L | 2021-10-14 |
20210317152 | IRIDIUM COMPLEX-CONTAINING COMPOSITION, ORGANIC LIGHT EMITTING DEVICE HAVING THE SAME, DISPLAY APPARATUS, IMAGING APPARATUS, ELECTRONIC EQUIPMENT, LIGHTING APPARATUS, AND MOVING BODY - A composition that contains an iridium complex and an isomer of the iridium complex, in which the amount of the isomer of the iridium complex is decreased. The iridium complex is a homo-N-trans (HNT) iridium complex having an iridium atom, and a first ligand, a second ligand, and a third ligand that are bonded to the iridium atom. The isomer has an iridium atom, a fourth ligand, a fifth ligand, and the third ligand. The composition ratio of the isomer relative to a total of the iridium complex and the isomer is 1.0% or less. | 2021-10-14 |
20210317153 | IRIDIUM (III) COMPLEXES CONTAINING N-HETEROCYCLIC CARBENE LIGAND, SYNTHESIS, AND THEIR USE THEREOF IN CANCER TREATMENT - Provided herein are Ir(III) complexes comprising N-heterocyclic carbene ligand, method of synthesis of the Ir(III) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Ir(III) complexes under both dark and light conditions. Also provided is a method of detecting the Ir(III) complex in a biological system. Also provided is a method of making the Ir(III) complex. The Ir(III) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo. | 2021-10-14 |
20210317154 | METHOD FOR PRODUCING SUGAR FATTY ACID ESTER BY TRANSESTERIFICATION REACTION - The invention provides a method for producing a sugar fatty acid ester characterized in that a fatty acid ester and a saccharide are allowed to react and transesterified using a weakly basic ion exchanger having a pK | 2021-10-14 |
20210317155 | Crystals of Glycyrrhizic Acid Derivatives, Crystalline Compositions, Pharmaceutical Compositions and Uses Thereof - This application belongs to the field of pharmaceutical technology, and relates to the crystals of glycyrrhizic acid derivatives, their crystalline and pharmaceutical compositions, and medical use thereof, and, in particular, to the crystalline form A, crystalline form B, crystalline form C, crystalline form D, and crystalline form E of magnesium isoglycyrrhizinate, the method of preparing the crystals, the crystalline and pharmaceutical compositions containing the crystals, and medical use thereof. The crystalline forms prepared according to this application have overcome the defects of the compound of Formula I prepared according to the prior art, such as solid caking, difficult filtration, hard drying, and poor clarity. They are also suitable for industrial production, and capable of improving product safety. | 2021-10-14 |
20210317156 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES - Embodiments of the invention are directed to new polymer linked multimeric guanosine-3′, 5′-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being activators of cGMP dependent protein kinase (PKG), and related monomeric precursors thereof. The invention is also directed to related monomeric compounds, which may also show modulating activity and/or may serve as monomeric precursors of the multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces. | 2021-10-14 |
20210317157 | Substituted Alloxazine Nucleosides and Nucleotides, and Methods of Making Same - The present disclosure includes nucleosides and/or nucleotides comprising an optionally substituted alloxazine (also known as benzo[g]pteridine-2,4(1H,3H)-dione, or isoalloxazine) at the anomeric position. | 2021-10-14 |
20210317158 | OPTICALLY ACTIVE SEGMENT FOR USE IN SYNTHESIS OF STEREOCONTROLLED OLIGONUCLEOTIDE, METHOD FOR PRODUCING THE SAME, AND METHOD FOR SYNTHESIZING STEREOCONTROLLED OLIGONUCLEOTIDE USING THE SAME - An optically active segment for use in synthesis of a stereocontrolled oligonucleotide represented by the following formula (I), a method for producing the same, and a method for synthesizing a stereocontrolled oligonucleotide therefrom are provided. In formula, B is a protected/unprotected nucleoside base; R | 2021-10-14 |
20210317159 | ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS - The present invention relates to an alkoxyphenyl derivative capable of synthesizing an oligonucleotide by a quicker liquid phase synthesis method than in the prior art, a protected nucleoside and a protected nucleotide to which the alkoxyphenyl derivative is bonded, a method for producing an oligonucleotide using the same, and a method for selectively removing the alkoxyphenyl derivative moiety and the like. A compound represented by the general formula (1) or a derivative thereof: | 2021-10-14 |
20210317160 | 3,4-THIAZOLO-STEROIDS AND METHODS OF MAKING AND USING THE SAME - 3,4-thiazolo steroids are provided herein. Also provided herein are methods of making and using the same for the inhibition of cell proliferation or the killing of cells. | 2021-10-14 |
20210317161 | A PROCESS FOR THE PREPARATION OF PASIREOTIDE - The present invention relates to a process for the preparation of Pasireotide of formula (I) and its acid addition salts. More particularly the present invention is directed to a process for the synthesis of Pasireotide of formula (I) having purity greater than 99.0% by HPLC using fragment coupling. | 2021-10-14 |
20210317162 | METHOD FOR EXTRACTION AND PURIFICATION OF HIRUDIN MUTANT AND USE THEREOF - Provided are a method for extracting a hirudin mutant, HV2-Lys47, from a fermentation broth of the hirudin mutant HV2-Lys47 produced by the fermentation of | 2021-10-14 |
20210317163 | Compositions And Methods For Simplified High Efficiency Isolation of Proteins - Compositions and methods are provided that simplify isolation of proteins of interest from serum or plasma. Finely divided silica or a similar lipid/lipoprotein binding solid is used in combination with a protein precipitating agent to generate a solution that includes the protein of interest and that can be applied to chromatography media without resulting in significant fouling of the media. The method is particularly suitable for isolation of immunoglobulin G. | 2021-10-14 |
20210317164 | TOMATO PLANTS ALLOWING THE ESTABLISHMENT OF MITES - The present invention relates to a modified Slmyc2 gene, which may comprise at least one modification as compared to the wild type sequence of SEQ ID No. 5, which modification leads to the reduction or absence of SlMYC2 protein activity, wherein the modified Slmyc2 gene is capable of conferring an aberrant glandular hair phenotype to a | 2021-10-14 |
20210317165 | ZP3 FRAGMENTS IN IMMUNOTHERAPY OF OVARIAN CANCER - The invention relates to zona pellucida protein (ZP3) fragments, and their use in immunotherapy of ovarian cancer. | 2021-10-14 |
20210317166 | ANTI-INFLAMMATORY USE OF PEPTIDE - Provided a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys or a salt thereof for use in the treatment of inflammation, of an inflammatory disorder and/or of ion thea condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis. | 2021-10-14 |
20210317167 | ANTIMICROBIAL PEPTIDES AND METHODS OF USE - Cyclic depsipeptide-class molecules, referred to herein as persephacins (including analogs thereof), having similarities to aureobasidin A, are described. The persephacins have antimicrobial activity, such as antifungal activity against a diverse range of clinically-relevant fungal pathogens, antiprotozoan parasite activity, and antibacterial activity, and can be used for example in treatments of difficult-to-treat ocular fungal infections at lower concentrations than natamycin. The active compounds may be combined with a secondary compound in a composition. | 2021-10-14 |
20210317168 | Complement Component 1s (C1s) Deficient Cells for Production of Vaccines and Biopharmaceutical Proteins - The present disclosure reports that a calcium-dependent serine protease, complement component is (C1s) has been identified as a protease responsive for cleavage of exogenous polypeptides expressed in mammalian cell lines such as CHO cells. These CHO cell lines provide for increased yield of antigenically correct, uncleaved exogenous polypeptide as compared to unmodified CHO cells expressing the active C1s protease. C1s-deficient cell lines and methods for use of same for producing exogenous polypeptides, e.g., human immunodeficiency virus (HIV) envelope glycoprotein polypeptides, such as, gp120 or human Factor VIII are provided. | 2021-10-14 |
20210317169 | STABILIZED HUMAN IMMUNODEFICIENCY VIRUS (HIV) ENVELOPE (ENV) TRIMER VACCINES AND METHODS OF USING SAME - The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention. | 2021-10-14 |
20210317170 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY AND TREATING VIRAL INFECTIONS - The present disclosure is directed to compositions and methods for targeted drug delivery that comprise a biocompatible framework carrying at least one drug and a viral surface protein, where the viral surface protein mediates entry into a target cell and is attached to an outer surface of the biocompatible framework in the drug carrier. | 2021-10-14 |
20210317171 | RECOMBINANT LECTIN VARIANTS - A modified lectin protein is provided having at least one amino acid modification in an amino acid sequence of SEQ ID NO. 1 or in an amino acid sequence having at least 60% homology thereto. The amino acid modification is selected from one of more of the following: at least one amino acid modification in a carbohydrate binding site; at least one amino acid modification in the N-terminus; at least one amino acid modification at position 76; or at least one amino acid modification at position 44 or 89. The modified lectin protein does not consist of the amino acid sequence of any of SEQ ID NOs: 2 to 4. | 2021-10-14 |
20210317172 | ANTIMICROBIAL PEPTIDE SCYREPROCIN OF SCYLLA PARAMAMOSAIN AND METHOD THEREOF - The present disclosure discloses an antimicrobial peptide Scyreprocin of | 2021-10-14 |
20210317173 | COMPOSITIONS AND METHODS FOR FABRICATING SYNTHETIC DRAGLINE SPIDER SILK - Compositions comprising a mixture of proteins derived from MaSP, nucleic acids encoding same and method for the preparation of synthetic dragline spider silk are provided. The compositions of the invention comprise a mixture of proteins of differing molecular weight, wherein each protein of said mixture comprises, independently, multiple repeats of a repetitive region of a MaSP (major ampullate spidroin) protein or a functional homolog, variant, derivative or fragment thereof. | 2021-10-14 |
20210317174 | COMPOSITIONS AND METHODS FOR DELIVERING CFTR POLYPEPTIDES - The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide (e.g., a human CFTR polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of a chronic lung disease, such as cystic fibrosis); and articles of manufacture or kits thereof. | 2021-10-14 |
20210317175 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-10-14 |
20210317176 | FG21 MUTANTS AND USES THEREOF - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2021-10-14 |
20210317177 | ACTIVATABLE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS - Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the CM1 and the CM2 function as a substrate for a protease; the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2. | 2021-10-14 |
20210317178 | PHARMACEUTICAL COMPOSITION COMPRISING POLYPEPTIDE - The present invention relates to a pharmaceutical composition including a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea, and has effects of reducing food intake, enhancing insulin secretion, suppressing gastric emptying, promoting lipolysis, and lowering a level of triglycerides. | 2021-10-14 |
20210317179 | PRECISELY ENGINEERED STEALTHY MESSENGER RNAS AND OTHER POLYNUCLEOTIDES - Present disclosure is directed to methods of lowering immunogenicity in long polynucleotide sequences by precise sequence engineering of immunogenic motifs in the polynucleotide sequences. This disclosure is further directed to precisely sequence engineered polynucleotides with improved functionality, such as displaying low innate immunogenicity, improved stability or high protein expression. In these polynucleotides, immunogenic sequence motifs are removed while conserving the remainder of the sequence. Compared to overall nucleotide alterations, this targeted engineering approach has unique advantages, including less disruption of the natural or optimized polynucleotide sequence, and hence, preservation of high expressivity while enabling stealthiness vis-à-vis the innate immune receptors. | 2021-10-14 |
20210317180 | NR2F6 INHIBITED CHIMERIC ANTIGEN RECEPTOR CELLS - Disclosed are compositions of matter, cells, and methodologies for generation of chimeric antigen receptor (CAR) cells with inhibited or absent NR2F6 activity. In one embodiment, a CAR possessing affinity to a tumor antigen is transfected onto T cells that possess reduced or absent NR2F6 activity, said reduction or absence of NR2F6 activity leading to increased production of cytokines associated with inhibition of tumor growth, metastasis or angiogenesis, and/or augmentation of tumor cytotoxicity. Inhibition of NR2F6 activity may be performed ex vivo on said T cells or in vivo by administration of small molecule inhibitors, siRNA, shRNA or gene editing. In some embodiments other immune cells are substituted for CAR-T cells. | 2021-10-14 |
20210317181 | UNIVERSAL CHIMERIC RECEPTORS - Disclosed herein are chimeric receptors and precursors, chimeric antigen receptors and precursors, universal chimeric receptor cell precursors, chimeric antigen receptor T cells, and methods of constructing and using the same. | 2021-10-14 |
20210317182 | Universal Immune Receptor Expressed by T Cells for the Targeting of Diverse and Multiple Antigens - The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain. | 2021-10-14 |
20210317183 | ENHANCED ANTIGEN PRESENTING ABILITY OF RNA CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES - The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens. | 2021-10-14 |
20210317184 | T CELL MODIFICATION - Improved compositions and methods for treating diseases, such as cancer, by providing a cell immunotherapy, wherein the cell immunotherapy is an immunomodulatory cell expressing an exogenous CD8 co-receptor and a modified T cell receptor (TCR) are provided. Also provided are polynucleotides, expression vectors, and immunomodulatory cells including the immunotherapy, as well as methods of generating said immunomodulatory cells. | 2021-10-14 |
20210317185 | MODULAR SYNTHETIC RECEPTORS AND METHODS OF USE - Modular synthetic receptors are provided. The synthetic receptors may include an extracellular domain capable of binding to one or more ligand molecules and may be released from the synthetic receptor after binding, a transmembrane domain derived from the Notch receptor, and an intracellular domain which may have one or more functional activities when released from the synthetic receptor. A method of use for the synthetic receptors is also provided, wherein upon binding of the extracellular domain to a specific ligand, the synthetic receptor undergoes proteolytic cleavage to release either or both the extracellular and intracellular domains. The extracellular binding domain, if released, may continue to bind to its cognate ligand and may carry one or more additional functional activities and the intracellular domain, if released, may stimulate or inhibit one or more intracellular activities. | 2021-10-14 |
20210317186 | METHOD OF TREATING AUTOIMMUNE DISEASE WITH LYMPHOCYTE ANTIGEN CD5-LIKE (CD5L) PROTEIN - Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40. | 2021-10-14 |
20210317187 | INTRACELLULAR DELIVERY OF BIOMOLECULES TO MODULATE ANTIBODY PRODUCTION - The present invention provides methods and systems for modulating antibody production by passing a cell suspension through a constriction, wherein the constriction deforms the cell thereby causing a perturbation of the cell such that a compound that modulates antibody production enters the cell. In some embodiments, the invention provides methods and systems for inducing de novo antibody production in cells. | 2021-10-14 |
20210317188 | COMPOSITIONS CONTAINING ACTIVATABLE ANTIBODIES - The invention provides a composition including an intact activatable antibody and a clipped variant thereof, methods of separating clipped variants of intact activatable antibodies from intact activatable antibodies and related methods including methods for determining or monitoring a relative percentage of an activatable antibody and a clipped variant thereof during a composition production process. | 2021-10-14 |
20210317189 | FORMULATIONS OF IMMUNOGLOBULIN A - Stabilized formulations for Immunoglobulin A and other biotherapeutic proteins. Formulations comprising at least one pH buffering agent at about pH 5 to about 8, optional non-ionic surfactant, and one or more optional stabilizing agents selected from the group consisting of amino acids, sugars/polyols, chloride salts, carboxylic acids, detergents, natural proteins, protein expression extracts, and mixtures thereof. | 2021-10-14 |
20210317190 | CANINE ANTIBODY LIBRARIES - The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries. | 2021-10-14 |
20210317191 | ANTI-RSV MONOCLONAL ANTIBODY FORMULATION - The present invention provides a formulation comprising: (i) an anti-RSV monoclonal antibody; and (ii) an ionic excipient; wherein the monoclonal antibody is present at a concentration of about 50 mg/ml or greater and the ionic excipient is present at a concentration of between 50 and 150 mM and the formulation has a pH of about 5.5 to about 7.5. | 2021-10-14 |
20210317192 | HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE - Disclosed herein are methods and compositions for treating a subject having or at risk of having an HIV infection. Disclosed herein are peptide immunogens and nucleic acids that have epitopes in which mutations are most likely to have deleterious effects on the HIV virus. An algorithm is disclosed for the selection of the epitopes based on the HIV fitness landscape, and it accounts for the effect of coupling mutations. | 2021-10-14 |
20210317193 | ANTIBODY SPECIFIC TO ALPHA-TOXIN OF STAPHYLOCOCCAL AUREUS AND USES THEREOF - The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically bind to α-toxin of | 2021-10-14 |
20210317194 | ANTIBODY FOR HAIR IMPROVEMENT USE - The present disclosure provides a composition and a method both for improving the hair. In one embodiment, the hair is improved using an antibody. In one embodiment, the antibody is produced using a bacterium occurring on the scalp or a hair root as an immunogen. In one aspect, the present invention also provides a method for improving the hair in a subject, including the step of administering an antibody produced using a microorganism-derived substance as an immunogen to the subject. The antibody according to the present invention may be administered in the form of a composition. According to the present invention, the promotion of hair growth or the prevention of hair loss can be achieved. | 2021-10-14 |
20210317195 | POLYPEPTIDES - There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions. | 2021-10-14 |
20210317196 | Methods of Treating Chronic Pain - The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody. | 2021-10-14 |
20210317197 | HUMANIZED ANTIBODY - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 2021-10-14 |
20210317198 | IDENTIFYING HUMAN B CELLS EXPRESSING ANTI‐ALLERGEN ANTIBODIES - In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen. | 2021-10-14 |
20210317199 | ALLERGEN-SPECIFIC ANTIBODIES - In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen. | 2021-10-14 |
20210317200 | ANTIBODY THAT RECOGNIZES NEOEPITOPE OF ACTIVATED INTERLEUKIN-18 PROTEINS AND APPLICATION THEREOF - Antibodies 9-10.2 and 8-4.1 that recognize YFGKLESK, which is 8 amino acids present in a neoepitope formed as a result of a precursor pro-IL-18 being cleaved by caspase-1 or caspase-4 are prepared. Accordingly, an antibody that recognizes only activated IL-18 can be provided. | 2021-10-14 |
20210317201 | ANTI-IL-23 ANTIBODIES - The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same. | 2021-10-14 |
20210317202 | USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE - The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1β binding antibody or functional fragment thereof. | 2021-10-14 |
20210317203 | AN IMMUNOTOXIN FOR TREATING CANCER - The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of | 2021-10-14 |
20210317204 | BI-SPECIFIC BINDING MOLECULES - The present invention relates to bi-specific antigen binding molecules and associated fusion proteins and conjugates. In particular, the present invention relates to bi-specific antigen binding molecules with specificity for both receptor tyrosine kinase-like orphan receptor 1 (ROR1) and epidermal growth factor receptor (EGFR) and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs). | 2021-10-14 |
20210317205 | NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF - This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, anemia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics. | 2021-10-14 |
20210317206 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2021-10-14 |
20210317207 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF - The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided. | 2021-10-14 |
20210317208 | ANTI-CD33 ANTIBODIES AND METHODS OF USE THEREOF - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | 2021-10-14 |
20210317209 | ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF - Provided herein are CD79b antibodies and CD79b-specific chimeric antigen receptors (CARs). Further provided herein are T cells expressing the CD79b-specific CARs and methods of treating cancer by administering the CD79b-specific CAR T cells. | 2021-10-14 |
20210317210 | CYTOTOXIC ANTI-LAG-3 MONOCLONAL ANTIBODY AND ITS USE IN THE TREATMENT OR PREVENTION OF ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE DISEASE - Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences. | 2021-10-14 |
20210317211 | METHODS OF USING ANTI-TREM2 ANTIBODIES - Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, using an anti-TREM2 antibody or antigen binding fragment thereof. | 2021-10-14 |
20210317212 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs - Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3. | 2021-10-14 |
20210317213 | Anti-CD3 Antibody Folate Bioconjugates and Their Uses - Described herein are novel anti-CD3 Folate antibodies and uses thereof in the treatment of diseases or conditions that would benefit from such. | 2021-10-14 |
20210317214 | COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST FOR TREATING PATIENTS WITH NON-MICROSATELLITE INSTABILITY-HIGH OR PROFICIENT MISMATCH REPAIR COLORECTAL CANCER - The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer. | 2021-10-14 |
20210317215 | ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOF - The invention provides methods for producing crystalline an anti-PD-1 monoclonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant, comprising (1) mixing a solution comprising (a) the mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of: caffeine, theophylline, 2′ deoxyguanosine-5′-monophosphate, a bioactive gibberellin, and a pharmaceutically acceptable salt of said bioactive gibberellin, to form a crystallization solution, (2) incubating the crystallization solution for a period of time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In specific embodiments, the PEG is PEG 3350 and the additive is caffeine. The invention also relates to the novel anti-human PD-1 mAb crystals produced by the methods described herein. Characterization of re-dissolved crystalline suspensions using several biochemical methods showed the bio-physical properties of the re-dissolved mAb crystals were consistent with the intact antibody starting sample. The crystals and methods of the invention are amenable to multiple pharmaceutical applications such as purification, storage, formulation, and drug delivery. | 2021-10-14 |
20210317216 | ANTI-FLT3 ANTIBODIES AND COMPOSITIONS - This invention relates to anti-FLT3 antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer. | 2021-10-14 |
20210317217 | HUMANIZED ANTI-VEGFR2 SINGLE-CHAIN ANTIBODY AND USE THEREOF - The present invention belongs to the field of antibody drugs, and relates to a humanized anti-VEGFR2 single-chain antibody and use thereof. The single-chain antibody comprises a heavy chain variable region set forth in SEQ ID No. 1 and a light chain variable region set forth in SEQ ID No. 2, wherein the heavy chain variable region and the light chain variable region are connected via a flexible peptide with an amino acid sequence set forth in SEQ ID No. 3. The present invention also discloses use of the antibody in preparing a product for inhibiting tumor growth. The antibody disclosed herein can be used as a medicament for clinical use in indications caused by neovascularization. | 2021-10-14 |
20210317218 | REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR - A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels. | 2021-10-14 |
20210317219 | Methods of Treating Conditions with Antibodies that Bind Colony Stimulating Factor 1 Receptor (CSF1R) - Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis. | 2021-10-14 |
20210317220 | METHOD OF PROVIDING SAFE ADMINISTRATION OF AN ANTI-CD154 ANTIBODY - Methods for clinically proven safe administration of an anti-CD 154 antibody or antigen binding fragment thereof by subcutaneous or intravenous administration are provided. Also provided are methods for clinically proven safe treatment of an autoimmune disease by subcutaneous or intravenous administration of an anti-CD 154 antibody or antigen binding fragment thereof, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and Sjögren's Syndrome. | 2021-10-14 |
20210317221 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES - Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNER2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases. | 2021-10-14 |
20210317222 | IMMUNOMODULATORY ANTIBODIES - The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof. | 2021-10-14 |
20210317223 | MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE - Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies. | 2021-10-14 |
20210317224 | ANTI-CLAUDIN 18.2 AND ANTI-4-IBB BISPECIFIC ANTIBODIES AND USES THEREOF - Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells. | 2021-10-14 |
20210317225 | MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 - Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes. | 2021-10-14 |
20210317226 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING POMPE DISEASE - Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload reduces glycogen levels in a cell. | 2021-10-14 |
20210317227 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS - The present disclosure relates to compositions and methods of engineered Fc-antigen binding domain constructs, where the Fc-antigen binding domain constructs include at least two Fc domains and at least one antigen binding domain. | 2021-10-14 |
20210317228 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS - The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. | 2021-10-14 |
20210317229 | EPCAM ANTIBODY AND CAR-T CELLS - The present invention provides EpCAM antibodies with different affinities. The present invention also provides chimeric antigen receptors (CARs) specific to EpCAM. CAR T cells comprising human EpCAM scFv having a low and sufficient affinity to EpCAM can avoid targeting healthy tissues with low EpCAM expression while exhibiting long-term efficacy against tumor tissues with high EpCAM expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human EpCAM scFv to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing EpCAM and kill the cancer cells. | 2021-10-14 |
20210317230 | FUSION PROTEIN AND USE THEREOF - Provided is a fusion protein, comprising a first binding domain that specifically binds a tumor-associated antigen, and a second binding domain that specifically binds a CD47 protein, wherein the second binding domain comprises a mutant of a human SIRPα variant 1. Also provided are an immunoconjugate, nucleic acid molecules, vectors, compositions, and cells related to the fusion protein and preparation methods therefor, and the uses thereof in the preparation of medicaments. | 2021-10-14 |
20210317231 | ANTI-5T4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES - The present invention relates to antibodies against the human 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable for testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgus monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4 antigen. The invention further relates to the use of the antibodies and corresponding ADCs in the treatment of solid tumours and haematological malignancies. | 2021-10-14 |
20210317232 | METHODS AND COMPOSITIONS RELATING TO ANTI-BIOTIN ANTIBODIES - Increasingly, human subjects are taking biotin as a medical therapy or nutritional supplement. This practice causes difficulty in analysis of biological samples, such as blood samples, using biotin conjugate reagents since free biotin results in interference. Inventive antibodies, and antigen binding fragments thereof, which specifically bind to biotin of a biotin conjugate and which have a higher affinity for biotin of a biotin conjugate than for free biotin, are provided along with methods of their use. | 2021-10-14 |
20210317233 | Super Versatile Method for Imparting New Binding Specificity to Antibody - The purpose of the present invention is to provide an efficient and versatile method for granting an additional binding activity to an antibody by inserting a peptide sequence into the antibody. The present invention provides a method of granting a binding ability to a second target molecule to an antibody, comprising inserting an internal peptide sequence of a cyclic peptide into an Fc region of the antibody, wherein the cyclic peptide has the binding ability to the second target molecule different from a first target molecule to be recognized by the antibody. | 2021-10-14 |
20210317234 | APOLIPOPROTEIN NANODISCS WITH TELODENDRIMER - The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R) | 2021-10-14 |
20210317235 | METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES - Processes for precipitating a polymer from a polymer-containing fluid are disclosed, which include providing a vessel housing a medium that provides one or more precipitation surfaces. A polymer-containing fluid, e.g., a polymer solution, dispersion or mixed solution/dispersion, and an anti-solvent can be introduced into the vessel so as to cause precipitation of at least a portion of the polymer on at least one of the precipitation surfaces. In some embodiments, the polymer contains one or more cyclic oligosaccharide moieties, such as one or more cyclodextrin moieties (e.g., α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin). The polymer can be any of a linear or branched polymer. The polymer can be any of polycation, a polyanion, or a non-ionic polymer. Also disclosed herein are precipitation surfaces with polymer precipitated thereon. | 2021-10-14 |
20210317236 | A MULTI-STAGE PROCESS FOR PRODUCING A C2 TO C8 OLEFIN POLYMER COMPOSITION - The present invention relates to a multi-stage process for producing a C | 2021-10-14 |
20210317237 | Method for Preparing Super Absorbent Polymer - The present disclosure relates to a method for preparing a super absorbent polymer that can appropriately control the water content of the super absorbent polymer by hydration or the like to suppress crushing or the like during transfer, and also can suppress deterioration of physical properties, such as production of giant particles and nonuniformity of water content during hydration step. | 2021-10-14 |
20210317238 | Bis(Metallocene) Compounds and Catalyst Compositions Employing Such Compounds - The present invention relates to new bis(metallocene) compounds, new catalyst compositions, process for preparing the new bis(metallocene) compounds and use of said new catalyst compositions to polymerise olefins. The bis(metallocene) compounds of the invention are homo- or hetero bis(metallocene) molecules in which same or different metallocene moieties are connected by a phenylene bridge. The phenylene bridge is either para-substituted, meta-substituted or ortho-substituted by the two metallocene moieties. | 2021-10-14 |
20210317239 | POLYOLEFIN CATALYST AND METHOD FOR PREPARING POLYOLEFIN USING SAME - Disclosed are a novel metallocene catalyst and a method for preparing a polyolefin having a high molecular weight and a low melt index by using the same. The present invention provides a transition metal compound represented by formula 1. | 2021-10-14 |
20210317240 | RESIN COMPOSITION AND USE FOR SAME - The present disclosure relates to a novel resin composition which imposes a reduced environmental load and which is excellent in dispersibility of fine polymer particles. Provided is a resin composition containing water, fine polymer particles (A) having a specific feature, and a thermosetting resin (B) having a specific feature. The resin composition contains the water, the fine polymer particles (A), and the thermosetting resin (B) in respective specific amounts, does not substantially contain an organic solvent, and contains sulfur (S) in an amount falling within a specific range and phosphorus (P) in an amount falling within a specific range. | 2021-10-14 |
20210317241 | RESIN COMPOSITION SUITABLE FOR PRINTING AND PRINTING METHODS - Embodiments of the invention relate to a resin composition, in particular suitable for printing, a kit comprising components of the resin composition, printing methods, a polymer obtained by the printing methods, an article comprising or formed from the polymer, uses thereof, and a composition. The resin composition comprises at least one compound C1 having at least one terminal alkyne functional group; at least one compound C2 having at least two thiol functional groups; at least one compound C3 having at least one carbon-carbon double bond; at least one photoinitiator; and at least one stabilizer. | 2021-10-14 |
20210317242 | PROCESS FOR PRODUCING A PREPOLYMERIZED SOLID ZIEGLER-NATTA CATALYST - The present invention relates to a process for producing a prepolymerized solid Ziegler-Natta catalyst in batch mode, a prepolymerized solid Ziegler-Natta catalyst, a process for producing a propylene polymer using said prepolymerized solid Ziegler-Natta catalyst, a prepolymerized solid Ziegler-Natta catalyst obtained by a process as well as the use of the prepolymerized solid Ziegler-Natta catalyst in a process for producing a propylene polymer. | 2021-10-14 |
20210317243 | METHOD OF PREPARING VINYL CHLORIDE-BASED POLYMER - The present disclosure provides a method of preparing a vinyl chloride-based polymer, and the method provides excellent productivity while having reduced amount of a volatile organic compound generated so as to provide the vinyl chloride-based polymer suitable for an eco-friendly material, and improved foaming and viscosity properties of a plastisol including the prepared polymer, by adding a carbonate-based metal salt and a transition metal catalyst together, and controlling input time and amount of the transition metal catalyst. | 2021-10-14 |
20210317244 | SILICONE HYDROGEL MATERIALS - A composition includes at least one siloxy-based (meth)acrylate monomer or prepolymer, at least one additional methacrylate monomer, UV, and Visible light blocking agents and one or more crosslinking agents. The final product results in a highly wettable material that possesses physical properties such as a low modulus of elasticity and high oxygen permeability without the need for a non-reactive solubilizing agent and that are free of cyclic and linear siloxanes. | 2021-10-14 |
20210317245 | METHOD FOR PRODUCING SUBSTRATE WITH PATTERNED FILM AND FLUORINE-CONTAINING COPOLYMER - The production method of a substrate with a patterned film according to the present disclosure includes: a cleaning step of performing UV/ozone cleaning or oxygen plasma cleaning on a substrate with a patterned film to obtain a first substrate with a patterned film, the substrate with a patterned film including a substrate and a patterned film on the substrate, the patterned film containing a fluorine-containing copolymer having a specific repeating unit; and a heating step of heating the first substrate with a patterned film to obtain a second substrate with a patterned film. | 2021-10-14 |
20210317246 | WATER REPELLENT OIL REPELLENT AGENT FOR FIBERS AND FIBER PRODUCT - A water- and oil-repellent agent for fibers containing a bottle brush polymer having a structure represented by the following formula (1), wherein R | 2021-10-14 |
20210317247 | SILICONE-ACRYLIC POLYMER PARTICLES - Provided is a polymer particle comprising
| 2021-10-14 |